Author + information
Hepatocyte growth factor (HGF) is a potent antifibrotic cytokine that has been reported to have an antifibrotic function in various pathological conditions, such as pulmonary, liver and renal fibrosis. And it has been recently reported to attenuate cardiac remodeling and function following myocardial infarction (MI). This study was designed to investigate whether this role could be strengthened by intramyocardial injection of HGF along with a novel Dex-PCL-HEMA/PNIPAAm hydrogel.
MI models were induced in rats by coronary artery ligation. Phosphate-buffered saline (PBS group), Dex-PCL-HEMA/PNIPAAm hydrogel (Hydrogel group), phosphatebuffered saline containing HGF (HGF group), and hydrogel containing HGF (Hydrogel+HGF group) were injected into the peri-infarcted myocardium immediately after myocardial infarction, respectively. The sham group was thoracic but without coronary artery ligation.
When delivered to the border zones following ischemia injury, the injection of HGF along with hydrogel reduced MI area, inhibited cell apoptosis, restrained collagen accumulation and improved cardiac function.
These data demonstrated that HGF injection along with Dex-PCL-HEMA/PNIPAAm hydrogel acquires more cardioprotective effects on rats post MI compared with single growth factor therapy.